PremiumThe FlyKura Oncology data overhangs receding, says BofA Kura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth Kura Oncology’s FDA Priority Review for Ziftomenib PremiumRatingsPositive Outlook for Kura Oncology: Buy Rating Supported by Promising Clinical Results and Strategic Advancements Kura Oncology price target lowered to $30 from $32 at Mizuho Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating PremiumCompany AnnouncementsKura Oncology’s Earnings Call: Key Highlights and Future Outlook Kura Oncology reports inducement grants under Nasdaq listing rule Kura Oncology: Strong Financial Position and Strategic Advancements Drive Buy Rating 
